A new study from Memorial Sloan Kettering Cancer Center shows good results for patients with pancreatic cancer. They used a personalized mRNA vaccine, which offers new hope. This pancreatic cancer ...

A new type of mRNA vaccine, added to standard cancer treatment, could help some patients with pancreatic cancer live longer.

About 60% of all cancer patients in the United States receive radiation therapy as part of their treatment. However, this ...

For decades, researchers have worked to create drugs that teach the immune system to kill cancer cells the way traditional ...

A new assay rapidly detected pancreatic ductal adenocarcinoma and differentiated it from noncancer pancreatic diseases by ...

Thanks to decades of sustained, predictable federal investments and increases in pancreatic cancer research, the research ...

Millions of American women are at high risk for breast cancer, but their insurance does not cover the costs of extra ...

As few as one in ten people survive pancreatic cancer five years after their diagnosis — making it the most difficult cancer to survive. The survival rate five years after diagnosis is 6-14%, but ...

Recent positive lab confirmation of Smart mRNA functionality is a tremendous milestone for the Company. This marks a ...

Clinical studies indicate that the mRNA vaccine may help treat pancreatic cancer, one of the deadliest cancers, reports ...

Clinical studies suggest that the mRNA vaccine may play a role in treating pancreatic cancer, identified as one of the most ...

Memorial Sloan Kettering Cancer Center researchers have found RNA neoantigen vaccines that generate long-lived, functional ...